Drug news
FDA extends review date of Uplyso (Pfizer)for Gauchers Disease until 1 May 2012
The FDA has extended its review by three months of the new drug application for Uplyso (taliglucerase alfa) from Pfizer/Protalix Biotherapeutics for the treatment of Gaucher's Disease .The effect delays the Prescription Drug User Fee Act action date until 1 May 2012. No additional data was requested by the FDA.